Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Wungki Park"'
Autor:
Johanna C. Bendell, Jack Shiansong Li, Wungki Park, John H. Strickler, Haeseong Park, Kartik Raghupathi, Wells A. Messersmith, Laura L. Carter, Jean-Marie Bruey, Drew W. Rasco, Jakob Dupont, Marya F. Chaney, Johann S. de Bono, Lei Zhou
Publikováno v:
Journal of Clinical Oncology. 39:2505-2505
2505 Background: GB1275 is a first-in-class, oral CD11b modulator that reduced myeloid-derived suppressor cells (MDSCs) and tumor associated macrophages (TAMs), repolarized M2 immunosuppressive TAMs to an M1 phenotype, resulting in increased tumor in
Autor:
Jakob Dupont, Wungki Park, Johanna C. Bendell, Laura L. Carter, Lei Zhou, Eileen M. O'Reilly, Anna Galkin, Jack Shiansong Li, Drew W. Rasco, Beatrice Ferguson, Andrea Wang-Gillam, Wells A. Messersmith, David Nickle, Marya F. Chaney
Publikováno v:
Journal of Clinical Oncology. 38:3085-3085
3085 Background: GB1275 is a first-in-class CD11b modulator that reduced myeloid-derived suppressor cells (MDSCs) and tumor associated macrophages (TAMs) at the tumor site, repolarized M2 immunosuppressive TAMs to an M1 phenotype, and increased tumor
Publikováno v:
BMJ case reports. 2018
We describe a rare case of severe autoimmune haemolytic anaemia (AIHA) in the setting of underlying chronic lymphocytic leukaemia receiving intravenous immunoglobulin, history of warm IgG autoantibody and treatment with nivolumab for advanced non-sma
Autor:
Alton B. Farris, Jerome C. Landry, Ganji Purnachandra Nagaraju, Wungki Park, LaTonia Taliaferro-Smith, Bassel F. El-Rayes, Roberto Diaz, Tua-Elisabeth Long
Publikováno v:
Molecular Carcinogenesis. 54:1147-1158
Epithelial to mesenchymal transition (EMT), invasion, and motility are essential steps in colorectal cancer (CRC) metastasis regulated by HIF-1α and NF-κB. Since HSP90 activates HIF-1α and NF-κB, we hypothesized that inhibition of HSP90 leads to
Autor:
Sarita Agte, Wungki Park, Naoyuki Okabe, A. Rahbari, Hiroyuki Suzuki, G. Lopes, Michael S. Oh, Deukwoo Kwon, Raja Mudad, Diana Saravia, Young Kwang Chae
Publikováno v:
Journal of Thoracic Oncology. 13:S696
Autor:
Ganji Purnachandra, Nagaraju, Purnachandra Nagaraju, Ganji, Wungki, Park, Jing, Wen, Hemchandra, Mahaseth, Jerome, Landry, Alton B, Farris, Field, Willingham, Patrick S, Sullivan, David A, Proia, Iman, El-Hariry, Latonia, Taliaferro-Smith, Roberto, Diaz, Bassel F, El-Rayes
Publikováno v:
Angiogenesis. 16:903-917
Hypoxia-inducible factors (HIFs) and STAT-3 play essential roles in angiogenesis. HIF-1α and STAT-3 are clients of the heat shock protein 90 (HSP90). We hypothesized that ganetespib, a potent HSP90 inhibitor, would disrupt angiogenesis in colorectal
Publikováno v:
Cellular Signalling. 25:1288-1300
Curcumin as an anticancer agent was investigated in regards to its ability to regulate the switching of cancer cells from survival to necrotic cell death. At higher concentrations, curcumin induced ROS production leading to JNK and p38 phosphorylatio
Autor:
Lydia Koenig, Wungki Park, Daniel Rycroft, Yuxiang Wang, Dong M. Shin, Sujin Yun, Steve Holmes, Sreenivas Nannapaneni, Hyung Ju C. Shin, Michael Steward, Thil Batuwangala, Hongzheng Zhang, Mourad Tighiouart, Lin Pan, Zhuo Georgia Chen
Publikováno v:
International Journal of Cancer. 131:956-969
An antibody simultaneously targeting epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF), two major tumor growth-driving machineries, may provide a novel effective strategy for optimizing tumor targeting and maximizi
Autor:
Gilberto Lopes, Wungki Park, G. Azzam, Lorraine Portelance, Nagy Elsayyad, Eric A. Mellon, Arnold M. Markoe
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 101:E24
Autor:
Vaia Florou, Deukwoo Kwon, Darcy A. Kerr, Efrosyni Sfakianaki, Jonathan C. Trent, Andrew E. Rosenberg, Ty K. Subhawong, Despina Kolonias, Jaime R. Merchan, Wungki Park, Eric D. Wieder, Krishna V. Komanduri, Matteo Trucco, Breelyn A. Wilky
Publikováno v:
Journal of Clinical Oncology. 36:11547-11547
11547Background: Inhibition of programmed-death 1 (PD1) by pembrolizumab (P) produced overall response rates (ORR) of 19% in advanced STS [SARC028]. Vascular endothelial growth factor (VEGF) suppre...